391
Participants
Start Date
June 30, 2012
Primary Completion Date
November 30, 2013
Study Completion Date
October 25, 2018
ofatumumab
"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
ibrutinib
ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
Site # 570, Dublin
Site # 528, Dublin
Site # 506, Wein
Site # 393, Antwerp
Site # 500, St Leonards
Site # 199, East Melbourne
Site # 501, Fitzroy
Site # 508, Linz
Site # 503, Brisbane
Site # 504, Salzburg
Site # 502, Nedlands
Site # 509, Graz
Site # 200, New York
Site # 350, New Hyde Park
Site # 510, Marseille
Site # 516, Caen
Site # 402, Philadelphia
Site # 522, Milan
Site # 523, Milan
Site # 526, Milan
Site # 210, Charlottesville
Site # 540, Madrid
Site # 537, Madrid
Site # 536, Madrid
Site # 396, Greenville
Site #107, Marietta
Site # 538, Pamplona
Site # 515, Bordeaux
Site # 518, Rennes
Site # 527, Padua
Site # 524, Modena
Site # 217, Columbus
Site # 520, Nantes
Site # 197, Cincinnati
Site # 379, Evansville
Site # 130, Detroit
Site # 517, Vandœuvre-lès-Nancy
Site # 406, Rochester
Site # 513, Clermont-Ferrand
Site # 032, Houston
Site # 381, Laredo
Site #377, Los Angeles
Site # 511, Bobigny
Site #403, Santa Maria
Site #038, Stanford
Site # 519, Argenteuil
Site # 404, Seattle
Site #408, La Jolla
Site #411, Norwalk
Site # 390, Boston
Site # 391, Boston
Site # 349, Boston
Site # 059, New Brunswick
Site # 127, Rochester
Site # 410, Nashville
Site # 505, Vienna
Site # 507, Wels
Site # 096, Galway
Site # 529, Gdansk
Site # 531, Lodz
Site # 539, A Coruña
Site # 535, Barcelona
Site # 534, Barcelona
Site # 533, Barcelona
Site # 549, Colchester
Site # 543, Sutton
Site # 551, Bournemouth
Site # 553, Canterbury
Site # 546, Cardiff
Site # 554, Headington
Site # 550, Leeds
Site # 552, Liverpool
Site # 544, London
Site # 548, Nottingham
Site # 545, Southampton
Site # 541, Withington
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Pharmacyclics LLC.
INDUSTRY